The persistent challenge of advanced HIV disease and AIDS in the era of antiretroviral therapy. Calmy, A., Ford, N., & Meintjes, G. A Clinical Infectious Diseases, 66(S2):S103–SS105, Oxford University Press, mar, 2018.
The persistent challenge of advanced HIV disease and AIDS in the era of antiretroviral therapy [link]Paper  doi  abstract   bibtex   
There has been tremendous progress in improving access to antiretroviral therapy (ART) over the past decade, supported by major scientific advances, national and international political and financial commitment, and civil society engagement. Overall global efforts to deliver ART at scale have been extremely successful in reducing mortality, and governments are committed to ending AIDS as a public health threat by 2030. Nevertheless, there is an increasing realization that there is a persistent and large burden of human immunodeficiency virus (HIV)–associated morbidity and mortality encountered in countries most affected by HIV. A substantial proportion of patients is still at risk of death due to progressing to advanced HIV—defined by the World Health Organization (WHO) as having a CD4 count \textless200 cells/µL or WHO clinical stage 3 or 4 disease—and this proportion has remained relatively constant in recent years despite ongoing improvements in access to ART
@article{Calmy2018,
abstract = {There has been tremendous progress in improving access to antiretroviral therapy (ART) over the past decade, supported by major scientific advances, national and international political and financial commitment, and civil society engagement. Overall global efforts to deliver ART at scale have been extremely successful in reducing mortality, and governments are committed to ending AIDS as a public health threat by 2030. Nevertheless, there is an increasing realization that there is a persistent and large burden of human immunodeficiency virus (HIV)–associated morbidity and mortality encountered in countries most affected by HIV. A substantial proportion of patients is still at risk of death due to progressing to advanced HIV—defined by the World Health Organization (WHO) as having a CD4 count {\textless}200 cells/µL or WHO clinical stage 3 or 4 disease—and this proportion has remained relatively constant in recent years despite ongoing improvements in access to ART},
author = {Calmy, Alexandra and Ford, Nathan and Meintjes, Graeme A},
doi = {10.1093/cid/cix1138},
file = {:C$\backslash$:/Users/Claire/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Calmy, Ford, Meintjes - 2018 - The persistent challenge of advanced HIV disease and AIDS in the era of antiretroviral therapy.pdf:pdf},
journal = {Clinical Infectious Diseases},
keywords = {OA,editorial,fund{\_}not{\_}ack},
mendeley-tags = {OA,editorial,fund{\_}not{\_}ack},
month = {mar},
number = {S2},
pages = {S103--SS105},
publisher = {Oxford University Press},
title = {{The persistent challenge of advanced HIV disease and AIDS in the era of antiretroviral therapy}},
url = {https://academic.oup.com/cid/article/66/suppl{\_}2/S103/4918987},
volume = {66},
year = {2018}
}

Downloads: 0